Scaling the Science: Technology Transfer
Summary
TLDRThe transcript discusses the complexity of manufacturing drugs, emphasizing that it's as challenging to produce them in sufficient quantities as it is to discover and validate the molecules themselves. It highlights the importance of consistency across global production sites, ensuring that the drug's quality remains high regardless of where it is made. The speaker details the technical efforts involved, such as adjusting for variations in materials and processes at different locations. The ultimate goal is to provide impactful medicines that improve patients' lives, underscoring the dedication to maintaining quality standards throughout production.
Takeaways
- 🔬 Manufacturing a drug at scale can be just as challenging, if not harder, than identifying the molecule and conducting clinical trials.
- 🌍 The global EMA status serves as the central coordination point for Roche and Genentech's worldwide sites, ensuring consistency regardless of where the product is made.
- 🛠 Flexibility in the supply chain is critical to ensure efficient manufacturing and delivery of drugs.
- 🌎 Collaborating with technical experts from different locations globally is challenging, but essential for solving complex problems.
- ⏳ Once the material reaches the filling facility, strict guidelines like validated hold times are critical to maintaining drug quality.
- ⚙️ Different production sites have unique variables, such as water quality, tank materials, and energy outputs, which all need to be harmonized for consistency.
- 🔄 Consistency across global plants ensures that patients receive the same drug quality, regardless of where it was produced.
- 🧠 Constant learning and adaptation are required even after initial drug discovery to ensure manufacturing processes maintain the highest quality standards.
- 💊 The impact of these drugs on patients' lives drives the commitment to meet timelines and deliver high-quality products.
- 🌟 The work done at Genentech has a significant positive impact on people's quality of life and society at large.
Q & A
What is one of the hardest parts of the drug development process according to the speaker?
-The speaker mentions that while it is easy to think that identifying the molecule, validating the target, and conducting clinical trials are the hardest parts, the reality is that ensuring the molecule can be manufactured in sufficient quantities consistently is just as hard, if not harder.
What role does the Global EMA team play within Roche and Genentech?
-The Global EMA team acts as a point of contact and serves as the 'glue' connecting various sites owned by Roche and Genentech around the world, ensuring that processes are executed, monitored, and delivered efficiently, regardless of where the product is manufactured.
What is the goal of the project mentioned in the transcript?
-The project aims to provide flexibility in the supply chain by ensuring that technical experts from different locations collaborate effectively to solve challenges and maintain consistency across manufacturing sites globally.
Why is consistency important in drug manufacturing according to the speaker?
-Consistency is crucial because the drug should be the same regardless of whether it is produced at one site or another. This ensures that the patient receives the same quality and efficacy, no matter where the product is manufactured.
What are some of the variables that need to be considered when transferring a process globally?
-Some variables include different kinds of water, the materials used to construct the tanks, flow rates, energy outputs, and the speed of pumps. All these factors must be standardized to maintain product consistency.
What has the engineering team already done to ensure consistency in the process?
-The engineering team has performed a series of mixing studies to validate and ensure that the manufacturing process remains consistent across different sites.
What is the importance of continuously learning about the molecule and the process even after development?
-Continuous learning is important to apply new knowledge to the manufacturing process and maintain the highest quality standards for the product, ensuring its efficacy and safety for patients.
How does the work at Genentech impact patients according to the speaker?
-The speaker mentions that Genentech receives feedback from patients who express how the drugs have positively impacted their lives. This feedback motivates the team to meet timelines and deliver high-quality products.
Why is flexibility in the supply chain important in drug manufacturing?
-Flexibility is important because it allows the company to adapt and maintain product consistency across various locations globally, despite differences in local conditions, resources, and regulations.
How does the speaker describe the overall impact of their work at Genentech?
-The speaker describes their work as highly impactful, influencing not only individuals but society as a whole by improving the quality of life for people through the drugs they produce.
Outlines
Этот раздел доступен только подписчикам платных тарифов. Пожалуйста, перейдите на платный тариф для доступа.
Перейти на платный тарифMindmap
Этот раздел доступен только подписчикам платных тарифов. Пожалуйста, перейдите на платный тариф для доступа.
Перейти на платный тарифKeywords
Этот раздел доступен только подписчикам платных тарифов. Пожалуйста, перейдите на платный тариф для доступа.
Перейти на платный тарифHighlights
Этот раздел доступен только подписчикам платных тарифов. Пожалуйста, перейдите на платный тариф для доступа.
Перейти на платный тарифTranscripts
Этот раздел доступен только подписчикам платных тарифов. Пожалуйста, перейдите на платный тариф для доступа.
Перейти на платный тарифПосмотреть больше похожих видео
HSO Dynamics 2009, Presentatie Meiny Prins, Zakenvrouw van het jaar 2009 (Priva)
Mini Materi: Good X Practice
Technology transfer in pharmaceutical industry
Ceramic tiles manufacturing process by Ceratec - How it's made?
Supply Chain Management PT. Garudafood Putra Putri Jaya - Kelompok 5
Biosimilars: Manufacturing and Inherent Variation
5.0 / 5 (0 votes)